These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 33333121

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
    Liu X, Hao R, Chen S, Guo D, Chen Y.
    J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C, Lu M, Yang D.
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [Abstract] [Full Text] [Related]

  • 26. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
    Kostyusheva AP, Kostyushev DS, Brezgin SA, Zarifyan DN, Volchkova EV, Chulanov VP.
    Mol Biol (Mosk); 2019 Oct; 53(2):311-323. PubMed ID: 31099781
    [Abstract] [Full Text] [Related]

  • 27. Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing.
    Li B, Zeng C, Li W, Zhang X, Luo X, Zhao W, Zhang C, Dong Y.
    Cell Rep; 2018 Dec 18; 25(12):3262-3272.e3. PubMed ID: 30566855
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V.
    AIDS Rev; 2017 Dec 18; 19(3):167-172. PubMed ID: 29019352
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
    Taha EA, Lee J, Hotta A.
    J Control Release; 2022 Feb 18; 342():345-361. PubMed ID: 35026352
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP, Jarrett KE, Lagor WR, Bissig KD.
    Gut; 2017 Jul 18; 66(7):1329-1340. PubMed ID: 28487442
    [Abstract] [Full Text] [Related]

  • 39. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
    Lin Y, Wilk U, Pöhmerer J, Hörterer E, Höhn M, Luo X, Mai H, Wagner E, Lächelt U.
    Small; 2023 Jan 18; 19(2):e2205318. PubMed ID: 36399647
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.